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Rabies, a zoonotic disease caused by infection with RNA viruses in the family Rhabdoviridae, genus 
Lyssavirus, is almost always fatal in humans.1 Canine 
vaccination and stray animal control programs imple-
mented in 1946 have significantly reduced domestic 
animal and human rabies cases in the United States 
from 8,384 domestic dog cases2,3 and 33 human cases in 
19462,3 to 75 dog cases2,3 and 2 human cases in 2008.4–6 
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During this same period, there was a marked increase 
in wildlife rabies. Raccoon rabies, first identified as a 
concern in the 1940s,3 became endemic in the Eastern 
states and Southern Canada.7–9 Most reported cases of 
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Objective—To determine the rate and absolute number of human and pet exposures to 
oral rabies vaccine (ORV) bait containing liquid vaccinia rabies glycoprotein recombinant 
vaccine and to evaluate factors that might affect human contact with bait to modify the 
program and reduce human exposure to the vaccine.
Design—Retrospective analysis of surveillance data (2001 to 2009).
Sample—Reports on human and pet contact with ORV baits in states with ORV surveil-
lance programs.
Procedures—Data were collected from passive, multistate ORV surveillance systems in 
Alabama, Arizona, Florida, Georgia, Maine, Maryland, Massachusetts, New Hampshire, 
New Jersey, New York, North Carolina, Ohio, Pennsylvania, Tennessee, Texas, Vermont, Vir-
ginia, and West Virginia. Data collected included the nature of human or pet contact with 
bait and vaccine, the caller’s knowledge of the ORV bait program, local human population 
density, and other relevant demographic data.
Results—All 18 states participated in the surveillance program for at least 1 year, for a com-
bined 68 years of observation. One thousand four hundred thirty-six calls were reported, 
representing 3,076 found baits (6.89/100,000 baits dropped); 296 (20%) calls were related 
to human contact with ruptured bait, and 550 (38%) involved pet contact with the bait. Six 
adverse events in humans were reported, one of which required hospitalization. Fifty-nine 
adverse events in pets were noted, all of which were nonserious.
Conclusions and Clinical Relevance—Findings from surveillance activities have been 
used to improve baiting strategies and minimize human and pet contact with ORV baits. 
Overall, human and pet contact with ORV baits was infrequent. Surveillance has led to 
early identification of persons exposed to ORV and rapid intervention. (J Am Vet Med Assoc 
2012;240:163–168)
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wildlife rabies occur among raccoons (Procyon lotor), 
skunks (primarily Mephitis mephitis), gray foxes (Uro-
cyon cinereoargenteus), and multiple species of bats, 
and these species are now the primary sources of rabies 
in dogs.8,10,11 Each year, an estimated 16,000 to 39,000 
persons in the United States come in contact with rabid 
and potentially rabid animals and receive rabies postex-
posure prophylaxis.5,12
Rabies control measures include vaccination of do-
mestic animals and surveillance programs to monitor 
rabies trends in humans and animals. Oral rabies vac-
cine programs were first initiated to complement tradi-
tional rabies control measures in Europe in 1977. The 
current USDA-licensed ORV consists of a rabies virus 
glycoprotein gene inserted into the thymidine kinase 
locus of the Copenhagen strain of vaccinia virus13,14,a; 
the deletion of a functional thymidine kinase results 
in attenuation of the virus.15 The oral vaccinia rabies 
glycoprotein recombinant vaccinea is packaged and dis-
tributed in heat-sealed plastic packets or sachets that 
are coated with fishmeal or placed within a fishmeal 
block to entice uptake by raccoons (P lotor), gray foxes 
(U cinereoargenteus), and coyotes (Canis latrans). Fol-
lowing oral exposure to the vaccine, the animals de-
velop neutralizing antibodies to rabies virus. The use of 
ORV began in Canada in 1985 and in the United States 
in 1990. In 1995, the USDA’s National Rabies Manage-
ment Program established the ORV program to prevent 
the further spread of wildlife rabies and eventually 
eliminate carnivore rabies in the United States through 
methods that involve the use of oral rabies vaccination 
targeting wildlife.16 It is anticipated that as the number 
of vaccinated animals in the population increases, de-
velopment of herd immunity will minimize the spread 
of disease to other wildlife, domestic animals, and 
humans. Oral rabies vaccine programs to combat the 
spread of raccoon rabies are currently ongoing in 16 
eastern states; in Texas and Arizona, baits are distrib-
uted for rabies control in gray foxes and coyotes.
Vaccinia virus, the viral component of the oral vac-
cinia rabies glycoprotein recombinant vaccine,a is an 
orthopoxvirus used as the viral vector of the vaccine. 
The vaccinia virus strain used in the ORVa has been 
attenuated. Nevertheless, human (percutaneous) ex-
posure to ruptured sachets can result in vaccinia virus 
infection.17,18 Severe outcomes are possible among per-
sons who are immunocompromised and for those with 
atopic dermatitis, exfoliative dermatologic conditions, 
and other conditions considered to be contraindica-
tions to smallpox vaccination.14,17,18
Since 1990, > 200 million doses of the ORVa have 
been distributed in the United States. However, reports 
of human and domestic animal contact with ORV baits 
have been relatively rare.8,19 In Pennsylvania, human ex-
posure to the liquid vaccine was reported to occur via 
dogs that find a bait and puncture the sachet when hu-
mans attempt to remove the bait from the dog’s mouth.19
Oral rabies vaccine bait distribution areas and 
methods (aerial or ground hand baiting) are selected to 
optimize opportunities to vaccinate wildlife but mini-
mize the chance of contact with non–target species, 
such as humans and pets. Fixed-wing aircraft are the 
most effective means for distributing large numbers of 
ORV baits. Hand baiting is important in urban and sub-
urban areas, where raccoon (P lotor) densities may be 
elevated and there may be limited habitat available for 
baiting as well as safety risks associated with distribut-
ing baits by air. Prior to baiting, communication cam-
paigns such as press releases, public service announce-
ments, and ORV media days at local airports where 
ORV operations are being coordinated are conducted 
to raise awareness. In addition, printed on each bait is a 
toll-free telephone number for the federal, state, or lo-
cal agency supporting the local ORV program. If a per-
son finds bait, he or she can call that number to obtain 
information about the ORV or to report (human or pet) 
contact with bait. This information forms the basis of a 
bait contact passive surveillance system.
State-based bait programs consist of 1 to 2 bait-
ing distributions/y, and surveillance for human and 
pet contact with bait is conducted annually. Surveil-
lance data have been used by agencies involved in ORV 
programs to improve local communications programs, 
modify baiting strategies, and reduce human and pet 
contact with baits by reducing aerial baiting in areas 
of high human population density and through better 
habitat targeting through hand baiting. The purpose of 
the study reported here was to determine the number of 
human and pet contact events with baits containing the 
ORV from 2001 to 2009. In this report, we also describe 
a severe adverse event in an immunocompromised in-
dividual reported to the surveillance system to illustrate 
how the surveillance system led to the prompt identifi-
cation of the patient.
Materials and Methods
Surveillance system—Since 2001, the USDA Wild-
life Services Program has maintained a surveillance sys-
tem of human and pet contact with ORV baits. Reports 
of human or pet contact with baits occur principally via 
1 of 2 mechanisms: from a citizen who has found the 
bait and calls the toll-free number printed on the baits 
or from federal or local agencies that were contacted 
after a bait was found. Additional information about 
the nature and circumstances of the contact is then 
collected by personnel in the appropriate local agency 
(typically a State or County Health Department). The 
nature of the information collected by individual juris-
dictions varies but usually includes the circumstances 
surrounding bait discovery, where it was found, how it 
was retrieved, and whether the sachet containing the 
vaccine was punctured. At the end of each ORV baiting 
season, federal and local offices in participating states 
complete a standardized surveillance questionnaire, 
which is designed to capture reports of human and pet 
contact with the bait. Eighteen states have participated 
in this surveillance system: Alabama, Arizona, Florida, 
Georgia, Maine, Maryland, Massachusetts, New Hamp-
shire, New Jersey, New York, North Carolina, Ohio, 
Pennsylvania, Tennessee, Texas, Vermont, Virginia, and 
West Virginia.
Statistical analysis—Surveillance forms were cre-
ated by use of commercial software,b and data were ana-
lyzed with statistical software.c Surveillance data were an-
alyzed to determine the rates of human and pet exposure 
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to ORV baits from 2001 to 2009. Rates of calls, exposures, 
and outcomes per 100,000 baits distributed are present-
ed. Frequencies for particular locations where baits were 
found, descriptions of the nature of human and pet con-
tact, and a summary of adverse events involving humans 
and pets were evaluated. Rate ratios were calculated to 
determine differences in the distribution of responses be-
tween geographic variables potentially affecting human 
contact with bait (bait density, human population density, 
and bait distribution method) and P values are reported. 
Low population density was categorized as < 150 people/
km2, high population density as ≥ 150 people/km2, low 
bait density as ≤ 75 bait-vaccine units/km2, and high bait 
density as > 75 bait-vaccine units/km2.
Results
From 2001 through 2009, > 80 million ORV baits 
were distributed in 18 states (Table 1). Number of years 
participating in the surveillance system during this pe-
riod differed among states; West Virginia, Ohio, Ver-
mont, New Hampshire, Texas, and New York each had 
program activities for the length of the surveillance pe-
riod (n = 9). Time with ORV bait program activities was 
8 years in Maryland, Pennsylvania, Virginia, Tennessee, 
and New Jersey; 7 years in Maine; 6 years in Florida, 
Georgia, and Alabama; and 5 years in North Carolina, 
Massachusetts, and Arizona. The cumulative number of 
baits distributed between 2001 and 2009 ranged from 
133,449 in Arizona to 24,172,750 in Texas. The sur-
veillance program captured information for a combined 
68 years of observation (50.7%); 44,635,548 baits were 
distributed during this observation period, and 3.51 
calls/100,000 baits distributed were reported (Table 2). 
The rate of calls to the helpline and the rate of bait in-
cidences varied over the surveillance period. The rate 
(per 100,000 baits distributed) of calls regarding pet 
contact with bait (2.53) was higher than the rate of calls 
regarding human contact with bait (0.47).
During the study period, there were 1,436 calls 
to the helpline and 3,076 baits were reported to have 
been found (6.89/100,000 baits distributed). The rate 
of baits found peaked in 2004 and then decreased to 
below 2001 values. Two hundred ninety-six (20%) 
calls were related to human contact with ruptured 
baits, and 550 (38%) involved pet contact with the 
bait, which were not mutually exclusive. The rates 
for pets finding bait, pets ingesting bait, and adverse 
events were 1.23, 0.70, and 0.08/100,000 baits distrib-
uted, respectively. Callers reported that pets had clini-
cal signs including lethargy, diarrhea, and vomiting. 
The rates of possible human exposure (defined as skin 
Table 1—Multistate vaccination programs that used oral vaccinia rabies glycoprotein recombinant vaccinea in the United States from 
2001 to 2009.
 No. of y of ORV program   Population Total No. of ORV baits
 activities (No. of y   density (No. of   distributed (No. distributed
State (year program began) captured in surveillance) Area (km2) people/km2)* during surveillance)
Alabama (2004)  6 (2) 8,569 190.67 4,279,161 (1,070,029) 
Arizona (2005)  5 (2) 1,400 141.98 135,449 (129,600) 
Florida (1995) 6 (6) 8,185 828.83 3,767,453 (3,025,449) 
Georgia (2004)  6 (2) 1,451 210.07 686,868 (342,487) 
Maine (2003)  7 (4) 690 366.63 632,123 (216,123) 
Maryland (2002) 8 (2) 1,086 1336.81 2,172,105 (154,710) 
Massachusetts (2008)  5 (2) 988 223.64 514,823 (147,036) 
New Hampshire (1997)  9 (4) 299 106.93 1,348,886 (429,605) 
New Jersey (1992)  8 (1) 480 199.54 359,200 (40,000) 
New York (1995)  9 (2) 20,003 365.61 11,135,545 (3,015,732) 
North Carolina (2005) 5 (2) 2,917 145.71 924,273 (419,455) 
Ohio (1998)  9 (9) 13,913 232.84 8,559,676 (8,559,676) 
Pennsylvania (2002)  8 (7) 12,637 266.63 7,595,083 (6,374,743) 
Tennessee (2002)  8 (2) 11,570 119.03 3,938,225 (1,286,637) 
Texas (1995) 9 (2) 107,599 21.19 24,172,750 (6,026,998) 
Vermont (1997)  9 (4) 7,255 54.16 2,245,992 (1,358,616) 
Virginia (2002)  8 (7) 5,053 60.67 2,619,735 (2,299,344) 
West Virginia (2001)  9 (8) 20,085 59.47 11,127,540 (11,127,540) 
Total 134 (68) 224,182 138 86,214,887 (44,635,548)
  *Population density of areas baited from 2008 census data.
Table 2—Number and rates (per 100,000 ORV baits distributed) 
of calls received during a 9-year (2001 through 2009) multistate 
surveillance period and rates of human and pet contact.
State Rate of Rate of human Rate of pet  
 calls (No.) contact (No.)* contact (No.)*
Alabama 3.46 (37) 0.09 (1) 1.60 (18)
Arizona 0.77 (1) 0.00 (0) 0.00 (0)
Florida 1.12 (68) 0.49 (4) 4.95 (40)
Georgia 1.46 (5) 0.00 (0) 0.58 (2)
Maine 16.19 (5) 0.00 (0) 1.66 (2)
Maryland 8.4 (13) 0.00 (0) 5.82 (9)
Massachusetts 38.77 (57) 6.59 (6) 54.94 (50)
New Hampshire 9.31 (27) 0.00 (0) 0.00 (0)
New Jersey 0 (0) 0.00 (0) 0.00 (0)
New York 3.42 (103) NA NA
North Carolina 0.95 (4) 0.00 (0) 0.24 (1)
Ohio 4.81 (412) 2.02 (45) 7.59 (169)
Pennsylvania 6.76 (431) 0.84 (16) 4.10 (78)
Tennessee 6.14 (79) 0.08 (1) 3.58 (46)
Texas 0.13 (8) 0.00 (0) 0.08 (5)
Vermont 2.65 (36) 0.72 (7) 2.48 (24)
Virginia 0.30 (7) 0.33 (2) 0.33 (2)
West Virginia  1.29 (143) 0.28 (7) 1.28 (32)
Total 3.51 (1,436) 0.47 (89) 2.53 (478)
  *Because of missing data, only information on rates of human 
and pet contact reported to the surveillance programs in 2008 and 
2009 was included.
  NA = Not available.
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contact with bait), probable skin exposure defined as 
skin or mucosa contact with broken bait, and adverse 
events were 0.66, 0.04, and 0.007/100,000 baits dis-
tributed, respectively (n = 6).
Adverse events in humans reported by callers in-
cluded rash, itchy skin, redness, and swelling. All of these 
involved someone having handled bait that had been rup-
tured by a pet dog. Five of the adverse events in humans 
involved skin rashes or dermatologic reactions, presum-
ably to the fishmeal bait, and 1 resulted in a serious 
vaccinia virus infection.20 Briefly, the Pennsylvania 
Department of Health received a report that a 35-year-
old woman, who was taking immunosuppressive medi-
cations to control symptoms of inflammatory bowel 
disease, picked up a bait ruptured by her dog. At the 
time, the woman had been picking blackberries and 
there were freshly abraded patches of skin on her right 
hand and wrist. Liquid vaccine leaked onto the abraded 
skin. When she returned home, after approximately 30 
minutes, she was able to call the ORV helpline number. 
The ORV helpline contacted a Public Health Physician 
at her state health department who was concerned be-
cause of the specific immunosuppressive agents taken 
and the type and degree of exposure. The women re-
ceived immediate instructions on what to look for and 
who to call if any lesions developed. Within 24 hours 
after the call, the women’s personal physicians and ex-
perts at the CDC were notified. Pictures of the injuries 
were obtained, and serologic analysis to obtain baseline 
data was performed. On day 4 following the exposure, 
she called again because several red papules appeared 
and she was subsequently diagnosed with vaccinia in-
fection20 (Figure 1).
Of 1,272 callers, 347 (27%) were aware of the 
ORV baiting program, and 928 of 1,404 (66.1%) had 
called the ORV helpline number. Forty-eight percent of 
baits were found on residential property, 42.7% were 
retrieved by pets, 5.8% were found on streets, and the 
rest were found in wooded areas. Human (R2 = 7.8; 
P = 0.024) and pet (R2 = 10.96; P = 0.043) contact 
with bait was considerably higher in areas of high hu-
man population densities (≥ 150 people/km2), com-
pared with contact in areas of low population densities 
(< 150 people/km2; Table 3). Ground baiting is the 
preferred method of bait distribution 
in areas with high human population 
densities, and baits are distributed at a 
low density (≤ 75 bait-vaccine units/
km2). Therefore, human and pet contact 
with bait increased as the percentage of 
ground baiting increased. Contact rates 
for both humans and domestic animals 
did not increase with higher bait density, 
presumably because baits are distributed 
at higher density in areas with lower hu-
man population density.
Discussion
Since 2000, > 100 million doses 
of the ORV have been distributed in 
the United States. The present study 
found that during the period from 2001 
through 2009, the rate of calls to the 
helpline remained relatively constant; a 
small increase was observed from 2007 
through 2009, which may have been re-
lated to sizable increases in surveillance 
participation. Nominally higher rates of 
found baits were observed during the pe-
Figure 1—Photograph of female human patient (age, 35 years) receiving immunosuppressive 
medications for inflammatory bowel disease, with vaccinia virus lesions and pronounced red-
ness and edema of her right hand on day 10 after contact with an animal ORV bait.
 Rate ratio (95% CLs)    Rate ratio (95% CLs)  
 of human contact   of pet contact  
Variable with bait P value with bait P value
Population density (high vs low) 7.80 (1.31–46.5) 0.024 10.96 (1.08–111.35) 0.043
Bait density (high vs low) 0.37 (0.116–1.21) 0.101 0.25 (0.05–1.23) 0.089
Ground baiting    
  $ 85% 9.00 (3.44–23.53) , 0.001 11.28 (3.57–35.64) , 0.001
  10%–85% Referent  Referent 
  , 10% 0.13 (0.01–1.91) 0.137 0.05 (0.00–8.43) 0.249
  Low population density was categorized as , 150 people/km2, high population density as $ 150 people/
km2, low bait density as # 75 bait-vaccine units/km2, and high bait density as . 75 bait-vaccine units/km2.
  CL = Confidence limit.
Table 3—Human and pet contact rates per 100,000 ORV baits distributed in 2008 in all states excluding 
Arizona, by human population and bait density.
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riod from 2001 to 2004; however, this may have been 
related to an increase in the number of bait distribution 
programs, given that 13 states initiated ORV bait pro-
grams during this period. Historically, the highest rates 
of found baits have been observed during the inaugural 
bait program in individual states. Enhanced surveil-
lance during this period is essential for modifications 
to future bait distribution plans.
Surveillance data suggest that human and domestic 
animal contact with ORV baits has been and contin-
ues to be rare. In the present study, the rate of reported 
contact with baits (1.29/100,000 baits distributed) was 
similar to those that have been found in other studies, 
which have ranged from 0.12 to 50 reports/100,000 
baits distributed.8,14,19,21 Pets continue to be the major 
source of human exposure to the liquid vaccine com-
ponent of ORV baits.14,19 Most baits were found by pet 
dogs, and all of the adverse events in humans were 
linked to retrieving bait from a pet dog. A published 
analysis19 of local surveillance data from Pennsylvania 
in 2003 demonstrated similar rates (66/70 pets that 
found baits were dogs).19 Furthermore, 7 of 8 human 
exposures to vaccine occurred after a dog had ruptured 
the sachet containing the vaccine in baits.19 Another 
analysis in Ohio indicated that 18 of 20 reports of prob-
able exposures to vaccine involved dogs; 3 of 20 reports 
involved persons with health conditions that are con-
traindications for vaccinia virus vaccination.14
The vaccinia rabies glycoprotein virus is a self-
replicating attenuated agent that may cause adverse 
events. Early identification of persons at high risk for 
developing serious vaccinia virus infection is important 
to avoid adverse outcomes. Surveillance and early de-
tection led to prompt identification of an immunocom-
promised individual who was exposed to vaccine liquid 
and allowed for a timely intervention. Medical person-
nel were alerted of possible vaccinia infection prior to 
symptom onset, and rapid implementation of treatment 
was possible.
In a previous study,8 increased human population 
density was also significantly related to increased rates 
of human and pet contact with the baits. The ORV pro-
gram uses ground (hand) baiting in areas with higher 
human population density to reduce the risk of human 
exposure. Given that there is a consequential relation-
ship between increased human and pet contact in ar-
eas with the highest ground baiting, low numbers of 
bait contacts may not be completely avoidable (Table 
3). Just as surveillance during inaugural programs was 
important to inform bait distribution plans to lower 
numbers of found baits, it remains essential in identify-
ing areas that may have demographic or other changes 
from season to season that lead to an increase in found 
baits. Continual surveillance is important for further 
refinement of bait distribution and identification of 
higher-than-expected rates of found baits.
Community outreach is an integral component of 
ORV programs. The extent to which outreach proved 
useful to those individuals who ultimately found baits 
(callers) could not be determined from the surveillance 
data summarized in this study because these data are 
not routinely collected at the state level. However, we 
did find that a large number of callers (n = 598) re-
ported that they did not know about ORV activities. 
Increased media outreach, public service announce-
ments, and newspaper advertisements may improve 
knowledge of the baiting campaigns,8,19 as in Pennsyl-
vania, where a sharp decrease in reports of bait contact 
from 2003 to 2004 (from 6.1 to 2.9/100,000 baits dis-
tributed) was attributed to modifications made to the 
program, including an increase in media outreach in 
smaller markets and increased hand baiting.19 The es-
tablishment of communication campaigns that support 
surveillance objectives through evolving social media 
such as microblogging and social networking services 
is currently under consideration.
The adverse event described in the present report is 
the second documented case of vaccinia virus infection 
associated with the ORV. The first instance involved a 
pregnant 28-year-old Ohio resident with epidermolytic 
hyperkeratosis who was bitten while pulling a ruptured 
bait from her dog’s mouth.14 During the course of a 34-
day infection, she developed swelling, erythema, left ax-
illary adenopathy, pustules, and necrotic scabs; her skin 
ultimately healed, and the pregnancy followed a normal 
progression.14 Both documented instances of human 
vaccinia virus infections caused by the ORV occurred 
after baits were found and the sachets were punctured 
by dogs,14,20 and all adverse events in humans involved 
interaction with pet dogs that found baits.8,14,19–21 These 
observations suggest that owners should not attempt to 
remove baits from their dog’s mouth and instead should 
use gloves or plastic bags to pick up and examine baits.
Results of data analysis in this report have several 
potential limitations. First, this is a passive surveillance 
system that relies on voluntary reporting, and it is like-
ly to underestimate the number of contacts with bait. 
Information collected from individuals calling differs 
among states; each state has its own surveillance form, 
and type of information and level of detail differ among 
states. Enhanced standardization of protocols is recom-
mended. Between 2005 and 2007, half of the ORV bait-
ing programs did not complete reporting to the surveil-
lance system. Increased follow-up to all states resulted 
in a sizable increase of participation, up to 95% in 2008 
and 2009.
The surveillance system in place has been useful in 
collecting timely pet and human ORV exposure data. 
Refinements and standardization of the surveillance 
system are needed, particularly at the individual pro-
gram level. Communication campaigns are an essential 
method to educate the public about ORV and the asso-
ciated risk of contact with baits and vaccine, and these 
should be modified during baiting activities to enhance 
outreach.
a.  Raboral V-RG, Merial Inc, Duluth, Ga.
b.  Adobe LiveCycle, Adobe Systems Inc, San Jose, Calif.
c.  SPSS, version 17.0, SPSS Inc, Chicago, Ill.
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